SAN DIEGO, April 17, 2011 /PRNewswire/ — Pharmatek
Laboratories, Inc., a premier contract development and
manufacturing organization supporting the pharmaceutical industry,
announced that it has been approved by the United States Drug
Enforcement Agency (DEA) for the analysis of Schedules I through V
controlled substances, complementing its existing license to
develop and manufacture drug products containing Schedules IV and V
controlled substances.
“Receipt of this additional registration from the DEA
demonstrates that we meet the Agency’s stringent requirements, and
further validates our facility design, security systems, and
procedures for analysis, handling, storage and disposal of
controlled substances,” said Jeffrey Bibbs, Ph.D, CEO and CSO at
Pharmatek. “This registration allows us to perform analytical
and stability testing for all controlled-substance drug products
within both our non-potent and highly-potent GMP facilities.”
Controlled substances are designated as Schedule I-V according
to their medical use, potential for abuse and safety or dependence
liability. In order to research, manufacture or distribute a
controlled substance, a person or entity must be audited and
registered by the DEA.
“The DEA registration is another example of our efforts for
continuous improvement and expansion of Pharmatek’s services,” said
Timothy Scott, President at Pharmatek. “As a client-centric
organization, our success is predicated on our ability to serve our
clients’ evolving needs. We are happy to bring this
additional capability to Pharmatek in order to serve that
purpose.”
About Pharmatek Laboratories, Inc.
Pharmatek Laboratories, Inc. is a premier pharmaceutical
chemistry development company providing full-service pharmaceutical
chemistry product development for the pharmaceutical industry.
Pharmatek focuses on bringing client compounds from discovery
to the clinic with services that includ
‘/>”/>